ALPMF - Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance

2025-01-30 17:06:04 ET

Summary

• Voyager Therapeutics, Inc.'s TRACER platform shows strong preclinical results for BBB-crossing gene therapies, securing multi-billion dollar deals with Novartis and Neurocrine, but lacks clinical trial data.
• VY7523, a monoclonal antibody for early Alzheimer's treatment, is expected to yield Phase I results by mid-2025, with potential undervaluation of VYGR shares.
• The competitive landscape includes Denali, Roche, and AbbVie, with varying BBB-crossing strategies, highlighting the speculative nature of investing in early-stage neurological therapies.
• I maintain a “Strong Buy” rating on VYGR shares for long-term, high-risk tolerant investors, emphasizing the speculative but promising potential of Voyager's TRACER platform and upcoming clinical trials.

Overview

About six months ago, I wrote an article on Voyager Therapeutics, Inc. ( VYGR ) highlighting the pipeline advances and stable financial position, supporting a “Strong Buy” rating. Given that VYGR’s shares have fallen by 35% since my last revision, and the upcoming Q4 report (02/28/25), I consider the stock worth an in-depth follow-up.

Voyager Therapeutics focuses on developing blood-brain-barrier ((BBB)) crossing treatments, including antibodies and gene therapies, to tackle neurological conditions such as Alzheimer’s disease ((AD)), Friedreich's Ataxia ((FA)), Huntington's disease ((HD)), amyotrophic lateral sclerosis ((ALS)), and Parkinson's disease ((PD)).

Voyager’s most advanced product candidate is VY7523, also known as VY-TAU01, which is their only product candidate that doesn’t involve their proprietary TRACER-capsids. VY7523, is a monoclonal antibody against pathological TAU ((pTAU)) for the early treatment of AD. In preclinical trials, VY7523 demonstrated its capacity to cross the BBB and specifically target pTAU after intravenous infusion. The Phase I single ascending dose ((SAD)) trial in healthy participants started in May 2024, and it is expected to yield the first top-line results in H1 2025. Those results will inform the multiple ascending dose ((MAD)) trial design, which is aimed to assess the therapeutic capacity of VY7523 in participants with early AD. The MAD trial is likely to start in H2 2025, and it is expected to yield results by mid-2026. Given that other p-TAU antibody-based therapies, such as Zagotenemab , from Eli Lilly (LLY), Gosuranemab , from Biogen (BIIB), and Bepranemab , from UCB Pharma (UCBJF), have reported Phase II clinical trial failures, investors should be truly interested in VY7523’s clinical trial performance....

For further details see: